Asthma drug showed positive results in trials for people with nasal polyps
An asthma drug has shown positive results when used to treat nasal polyps, researchers have said.
Tezepelumab was first approved for treating asthma in 2021, but new research led by a University of Dundee professor has found it also reduces the size of nasal polyps and nasal blockages.
The results, published in the New England Journal of Medicine, say significant results were reported by users in as little as two-to-four weeks, compared with those who were given a placebo.
Other outcomes were reported, including improved smell and quality of life, and underlying sinus problems were also alleviated in some individuals.
The global trial was co-led by Professor Brian Lipworth, of the University of Dundee's school of medicine, a practicing consultant physician working in the departments of respiratory medicine and ear, nose and throat clinics.
Professor Lipworth, who is also head of the Scottish Centre for Respiratory Research, said: 'These results represent an important breakthrough in terms of therapy for patients suffering from severe chronic rhinosinusitis and nasal polyps.
'I treat patients who are already using this drug for asthma – around a third of patients who have severe asthma also have nasal polyps.
'Many of them were reporting that their nasal polyp symptoms and related quality of life were greatly improved shortly after taking this drug in the clinic, where we also noticed their polyps had shrunk.
'However that was just real-life clinical experience, so it's fantastic to confirm that it can treat this condition too in the setting of a proper placebo-controlled trial.'
The drug, which has been approved in the UK for its use against asthma, is produced by pharmaceutical giants AstraZenica and Amgen.
The trial marks the first time the drug has been tested for treating nasal conditions.
Nasal polyps are thought to affect around 5% of the total population in the UK, and around 20% of patients with asthma.
A total of 408 participants with severe chronic rhinosinusitis and nasal polyps, from ten different countries, were involved in the trial, named 'Waypoint', with 203 of those being given the active drug injections and the others being issued with a placebo.
All participants received a monthly dose over 52 weeks and the nasal polyps were then inspected with a telescope and symptoms reported as well as sinus scans, nasal flow measurement and formal smell testing.
John Ellerby, 70, of Tayport, Fife, has suffered from nasal polyps for nearly 40 years and has undergone three surgical procedures to remove growths from his sinuses.
He describes his condition as being akin to a 'one-way valve' through which he can breathe in but not out.
His symptoms include a constantly blocked nose, headaches, earaches, breathlessness to the point of needing an inhaler, coughing and mucus coming from his nose unnoticed.
The condition also affects his sleep and his moods, leading to irritability.
Despite not being initially told if he was given the active drug Tezepelumab or the placebo, Mr Ellerby says it became very clear to him when his sense of smell returned, around three months into the trial.
He said: 'I was going around the house sniffing everything – coffee, perfume, the flowers in the garden. It was fantastic.
'I walked along the beach enjoying the smell of the sea, I started playing squash again, and I was out with the dog doing 14,000 steps a day.
'I was doing things I hadn't been able to do since my 30s, I felt like a new man.'
Professor Lipworth says medicinal organisations such as the Scottish Medicines Consortium (SMC) and the National Institute for Health and Care Excellence (Nice) will ultimately advise the NHS on whether the drug should be rolled out on prescription.
The NHS will then decide if the drug is cost-effective and fit for purpose.
Hopeful the drug will be approved for treating nasal polyps, he said: 'All being well, if the price is right, Nice and SMC will decide on whether it's cost effective.
'Other drugs have gone through the same process but have been rejected on cost-effectiveness, so that's the problem, so we'll have to wait and see.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 hours ago
- Yahoo
Europe suffers its largest diphtheria outbreak in 70 years
The largest diphtheria outbreak to strike Western Europe in 70 years has been affecting vulnerable people such as migrants and the homeless since 2022, new research said Wednesday. Diphtheria is a highly contagious bacterial infection that can attack the respiratory tract and spread throughout the body, causing a sore throat, fever and other symptoms. For unvaccinated people, it can be fatal in around 30 percent of cases, and is deadlier for children, according to the World Health Organization. In 2022, there was an unusual surge in the bacteria that causes diphtheria -- Corynebacterium diphtheriae -- in several European countries, particularly among recently arrived migrants, according to a study in the New England Journal of Medicine. That year 362 cases were recorded by the European Centre for Disease Prevention and Control. Contact tracing and screening helped tamp down the outbreak, but rare infections have continued to be recorded, the researchers said. A total of 536 cases, including three deaths, have been recorded across Europe since the start of 2022. Patient samples from 10 countries showed that 98 percent of the cases were in males with an average age of 18. Almost all had recently migrated. "The outbreak, which mainly affected migrants from Afghanistan and Syria, was not the result of people being infected in their countries of origin, but during their migration journeys or in their places of accommodation in European countries," said a joint statement from France's public health agency and the Pasteur Institute. The genetic similarities between the strains seen in people from different countries suggests that there was a "recent point of contact, outside the country of origin" at the source of the outbreak, the statement added. The exact areas affected by the outbreak remains unclear. But a genetic link between the 2022 strain and the one detected in Germany this year indicates that "the bacteria continues to circulate quietly in Western Europe," the statement said. Vaccination is very effective at fending off diphtheria, and the researchers emphasised the importance of immunisation programmes for the general public. They also called for European nations to do more to ensure their most vulnerable people avoid contracting the disease. That included raising awareness of the symptoms among doctors and those in contact with migrants and the homeless, as well as increasing access to vaccines and antibiotic drugs. ic-dl/giv
Yahoo
2 days ago
- Yahoo
Exercise proves powerful in preventing colon cancer recurrence
New evidence has linked physical activity with improved colon health, underscoring the vital role of exercise in cancer prevention and care. The landmark international trial – the Challenge study – showed that structured exercise programmes can dramatically improve survival rates for colon cancer survivors. The study was unveiled at the meeting of the American Society of Clinical Oncology. Each June, cancer specialists from around the world convene in Chicago for the conference where new research is announced that pushes the boundaries of cancer treatment and this year's conference featured a wealth of exciting discoveries. Conducted across six countries and published in the New England Journal of Medicine, the Challenge study tracked 889 patients for several years following chemotherapy. Participants were randomly assigned to one of two groups: one received standard post-treatment care, while the other took part in a three-year coaching programme that included personalised exercise plans and regular check-ins with fitness professionals. The results were striking. Those in the exercise group experienced 28% fewer cancer recurrences and 37% fewer deaths. Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. In the programme, people slowly built up how much they exercised, with most choosing to go on brisk 45-minute walks four times a week. Ninety per cent of the people who exercised stayed cancer free for five years, compared with just 74% of those who didn't. This study provides the first strong evidence that exercise not only correlates with better outcomes but directly improves survival rates in cancer patients. While earlier observational studies found a link between being active and better cancer outcomes, this first randomised controlled trial helps show causation, meaning that exercise can directly benefit the survival of cancer patients. We don't know yet if the same goes for other cancers like breast, prostate or lung, but it's a big step forward. The programme's success hinged on consistent support. Participants met with fitness coaches every two weeks at first, then monthly, which helped them stick to their routines even after treatment ended. While minor injuries such as muscle strains were slightly more common among those who exercised (19% compared to 12% in the control group), researchers emphasised that these issues were manageable and far outweighed by the significant survival benefits. In contrast to the encouraging findings on structured exercise, a separate study presented in Chicago has raised questions about the potential downsides of extreme endurance training. Researchers tracking marathon runners found a higher rate of polyps (small growths in the colon that can sometimes develop into cancer) compared with the general population. This unexpected finding has sparked a fresh debate about the effect of high-intensity exercise on long-term colon health. However, context is needed. The study did not find higher cancer rates among runners, and most of the detected polyps were low risk. Several possible explanations have been offered: endurance athletes may simply undergo more frequent screenings, leading to increased detection, or intense exercise might temporarily raise inflammation markers. Crucially, the overall risk of cancer remains lower in active people than in those who are more sedentary, reinforcing the well-established protective benefits of regular exercise. This apparent contradiction highlights the medical community's evolving understanding of the 'dose' of physical activity. While moderate exercise is consistently linked to significant health benefits, emerging data from endurance athletes suggests that extreme, high-intensity training may place different kinds of stress on the body's systems. Researchers also suggest that factors such as dehydration during long-distance runs, changes in gut function, or the use of certain nutritional supplements common among endurance athletes could play a role in polyp development. These findings don't diminish the well-documented benefits of physical activity, but instead point to the importance of personalised, balanced health strategies. For cancer survivors, the structured exercise study provides a message of practical hope. Participants aimed for the equivalent of about three hours of brisk walking per week, gradually increasing their activity levels over time. The programme's social support was key, with fitness coaches helping participants tailor their routines to match their abilities and recovery needs. Exercise is believed to affect key biological processes – including insulin sensitivity, inflammation and immune function – that play important roles in cancer development and progression. Ongoing research is analysing participants' blood samples to better understand these mechanisms and eventually create personalised exercise 'prescriptions' based on an individual's genetic profile. While the findings from marathon runners are less conclusive, they still offer practical takeaways. The research suggests that although vigorous exercise is generally beneficial, high-intensity athletes may face a higher risk of developing polyps and should therefore consider regular colonoscopies as a precaution. For the general public, these findings reinforce that combining moderate exercise with timely screenings offers the best protection against colon cancer, a disease that remains the fourth most common worldwide and is alarmingly increasing among young people. For both patients and athletes, these findings highlight a central truth: movement matters, but the right approach is crucial. Colon cancer survivors now have proven tools to reduce recurrence through structured exercise, while endurance enthusiasts gain motivation to pair their training with preventative care. As science continues unravelling the intricate dance between activity and biology, one message remains clear: whether recovering from illness or chasing personal bests, informed exercise combined with medical guidance is the most reliable path to long-term health. This article is republished from The Conversation under a Creative Commons license. Read the original article. Justin Stebbing does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
National Geographic
2 days ago
- National Geographic
MSG is making a comeback. But was it ever really that bad for you?
For years, advertising and media connected the ingredient to 'Chinese Restaurant Syndrome.' Here's what led to the misconception—and how MSG is being reclaimed today. Monosodium glutamate, or MSG, is a common ingredient across Asian cuisines. But its history is riddled with false health claims and misinformation. Photograph by Penchan Pumila / Alamy Stock Photo MSG's reputation has been on the mend for years. Once blamed for dubious health concerns like headaches, numbness, and chest pains, the ingredient now appears in cocktails, cookies, and influencer pantry tours with growing pride. But MSG's cultural redemption hasn't happened in a vacuum. Ajinomoto—the world's largest producer of monosodium glutamate, or MSG—has played a quiet but consistent role in reshaping how we think about the additive. And a wave of Asian American chefs and creators, including David Chang in a 2012 TED Talk, have been reclaiming it over the last decade, pushing back against decades of xenophobia and misinformation. (The surprising story of how chili crisp took over the world.) What is MSG? First isolated from kombu in 1908 by Japanese chemist Kikunae Ikeda, monosodium glutamate was hailed as a scientific breakthrough—a crystalline distillation of umami. A year later, Ikeda helped establish Ajinomoto to manufacture and distribute the seasoning commercially. Marketed as a kind of culinary enlightenment, the ingredient's popularity spread quickly across East and Southeast Asia. Restaurants stocked it tableside; ads described it as refined, nutritious, and essential for the modern household. In the United States, MSG gained traction after World War II, when returning American soldiers remarked that Japanese rations tasted better than their own—a difference attributed, in part, to the use of MSG. The seasoning caught the attention of food scientists and entered American kitchens in the late 1940s. From miracle powder to cultural scapegoat By the 1950s, MSG was a staple of industrial kitchens and processed foods—from canned soups to frozen dinners—embedding itself in the architecture of quick and easy American food. Then came the backlash. In 1968, a Chinese American physician named Robert Ho Man Kwok wrote a letter to the New England Journal of Medicine, describing symptoms—numbness, weakness, palpitations—he occasionally experienced after eating at Chinese restaurants. He suggested MSG as a possible cause, among other ingredients like salt and soy sauce. Readers wrote in claiming similar experiences, and soon, 'Chinese Restaurant Syndrome' entered the cultural lexicon. A year later, a paper in Science authored by a neurologist gave the MSG theory scientific veneer, despite what modern researchers have described as questionable, anecdotal evidence. MSG quickly became a scapegoat for anxieties around Chinese food. Restaurants began displaying 'No MSG' signs to reassure diners, and at one point, the U.S. government considered restrictions on MSG. (How the humble soybean took over the world.) Yet decades of scientific studies have failed to find a consistent link between MSG and these alleged symptoms. Major health organizations, including the U.S. Food and Drug Administration, World Health Organization, and European Food Safety Authority, have concluded that MSG does not pose a health risk when consumed at typical dietary levels. A 1995 FDA analysis stated that there is 'an absence of data to support a neurotoxic effect from MSG at levels required to produce a flavor-enhancing effect.' 'Every major public health organization has reviewed the evidence,' says Tia Rains, vice president of science at Ajinomoto. 'When it's used as seasoning in food, it is not harmful to the public,' though it can pose risks if consumed in large amounts. Over the past five years, Ajinomoto has sponsored educational content, partnered with influencers, and pushed to correct long-standing myths around MSG's safety. They're also actively pushing back against critics. In a 2022 advertising dispute in Brazil, Ajinomoto filed a complaint with the country's advertising self-regulatory body, the National Council for Advertising Self-Regulation (CONAR), alleging that a Burger King ad campaign misled consumers by unfairly implying that MSG was harmful. Ajinomoto initially won, arguing the ads unfairly targeted MSG, but the decision was overturned when CONAR ruled that the negative implications about MSG were subjective and fell within the bounds of commercial free speech. MSG and the discovery of umami In fact, the groundwork for MSG's rehabilitation began well before the glossy explainers and branded partnerships; it started in the 1980s with a scientific campaign to legitimize umami. At the helm was Kumiko Ninomiya, a biochemist who spent 40 years in Ajinomoto's global communications department and became known as the 'Umami Mama.' She set out to prove that umami wasn't just a flavor, but the fifth basic taste with its own receptors, putting it on equal footing with sweet, salty, sour, and bitter. (Who is General Tso—and why does he have his own chicken dish?) With Ninomiya leading the charge, Ajinomoto helped establish the Umami Information Center, where they organized international symposiums bringing together scientists to explore the sensory basis of umami. The breakthrough came in the early 2000s, when a group of independent American researchers identified a taste receptor specifically for glutamate, cementing umami's status alongside the other four basic tastes. That finding helped reframe MSG—not just as an artificial additive, but as a purified form of something elemental. Ajinomoto played a central role in promoting those findings. 'When scientists discovered the glutamate receptor, that news spread around the world,' says Ninomiya. 'We decided to share that information more widely to chefs and nutritionists.' Today, that scientific validation underpins a broader cultural shift—one shaped by genuine enthusiasm, but also by a corporate narrative that has quietly blurred into cultural reclamation. When identity, science, and branding align, it can be hard to tell who's leading the conversation. Chefs go out of their way to praise MSG's transformative effect on food; content creators flaunt it in videos; dietitians even recommend it to clients seeking more flavor with less sodium. 'I focus on helping people have an enjoyable relationship with healthy food,' says Kathleen Benson, a registered dietitian in El Paso, Texas. 'Umami is key for that satisfaction, and MSG is one of the tools we can use to enhance it.' That practicality has begun to resonate—especially among a new generation of Asian American chefs and recipe developers reclaiming the ingredient their predecessors were once shamed for. Award-winning cookbook author Kat Lieu, known for her Asian-inflected bakes—like a fish sauce chocolate chip cookie spiked with bourbon—uses MSG to temper bold flavors. 'If you have too much fish sauce, it gets very pungent,' she says. 'But then with that dash of MSG, everything just gets elevated. For Calvin Eng, chef-owner of Bonnie's, a Cantonese American restaurant in Brooklyn, MSG isn't just an enhancer—it's a fixture. 'Like salt and sugar, it's something I always have on the counter,' he says. Though Eng grew up with chicken powder, which contains MSG, he didn't start cooking with pure MSG until working in restaurants. Now, he uses it across the board: fries, desserts, even martinis. 'When you have sweet, savory, umami—it just makes things more special and unique.' His debut cookbook, Salt Sugar MSG, puts the ingredient front and center. 'I was afraid my publisher would say it's not marketable,' he recalls, about including MSG in the title. 'But they were cool with it, and it stuck.' For some, embracing MSG also means unlearning inherited stigma. 'I grew up thinking MSG was bad for you,' says Jenn Ko, co-founder of Dime, a playful MSG brand aimed at making the ingredient feel more approachable. 'My family always looked for restaurants that advertised 'No MSG.'' Her turning point came when she saw a friend buying MSG at the market. 'I started digging into the history—how it was vilified, how that one letter started it all.' Ko, Eng, and Lieu are part of a broader wave of Asian Americans embracing MSG—not just as seasoning, but as a proud marker of cultural identity. In 2024, Lieu and Eng signed an open letter written by Ajinomoto urging the New England Journal of Medicine to revisit the term 'Chinese Restaurant Syndrome' and its role in decades of racialized fear. The journal never responded. For Lieu, much of the stigma around MSG comes down to perception. 'MSG is just three letters, so people assume it's some scary chemical,' she says. 'But if you think about it, all food is made of chemicals. Let's stop with the racist mentality of treating it like a toxin.'
